New drug combo tested for Tough-to-Treat cancers
NCT ID NCT06220318
Summary
This study is testing a new drug called C019199 combined with an existing immunotherapy (sintilimab) for people with advanced solid tumors that have stopped responding to standard treatments. The first part aims to find a safe dose, and the second part will see how well the combination works to control cancer growth. It involves about 155 adults whose cancer has progressed despite other therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hunan Cancer Hospital
Changsha, Hunan, China
-
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
Conditions
Explore the condition pages connected to this study.